37 - HEALTHCARE COMMS

Trinity Life Sciences (Trinity), a global leader in life sciences solutions, and Havas Health & You (HH&Y), the world’s largest global health and wellness network and part of Havas Group, a Vivendi (VIV) business, today announced a strategic partnership that will allow both companies to offer cohesive end-to-end commercial solutions to the life sciences industry. The partnership includes HH&Y taking a minority investment in Trinity.

“The rapid and dynamic pace of the life sciences industry requires we take a more comprehensive view to move smarter and faster. The combination of Trinity and HH&Y provides expertise and capabilities through all stages of the pre-commercial and commercial life cycle,” said Donna Murphy, global chief executive officer, Havas Creative Group and HH&Y. “Modern technologies are helping to fuel incredible innovations in health, and this brings new challenges – this partnership enables us to best meet the industry’s needs.”

“When we started to talk about the potential partnership, it became clear that both Trinity and HH&Y had missions that were solidly aligned. Both companies know every decision impacts a life, and it is what gets us up in the morning,” said David Fitzhenry, chief executive officer of Trinity. “To layer on sophisticated data, insights and analytics to branding and communications programmes for our collective life sciences clients will be industry-changing. Addressing key areas such as launch, customer experience and application of technologies to advance omnichannel will be our focus.”

The Trinity/Havas partnership is the latest in a line of strategic moves for Trinity. Last year, Trinity acquired D Cube Analytics, a data science and analytics provider, and announced a partnership with Bain & Co.

“The partnership is a strategic move for both Trinity and Havas and will help to revolutionise how brands are built for life sciences companies,” said Matt Jennings, operating partner of Kohlberg & Co and chairman of Trinity. “Clients will see offerings that address new product planning projects with earlier stage strategic brand communications, as well as marketing campaigns that are driven more directly by objective insights and analytics.”

Lucid Group (Lucid) has acquired leading consulting firm Synetic Life Sciences (Synetic). The combined capabilities of Lucid and Synetic represent a unique value proposition for the industry, providing clients with an end-to-end partnership across the development and commercialisation journey, delivering transformative solutions across clients’ organisational needs and brand opportunities.

It is a significant step forward for Lucid in its mission to improve global health outcomes by building an organisation designed for today’s healthcare challenges and capable of disrupting the service provider model.

Dennis O’Brien, Lucid Group CEO, commented: “Our goal has been to purposefully design an organisation with the capabilities to have a transformational impact for clients’ organisations, for their medicines and for the patients who will ultimately benefit from them. We have been searching for a consultancy with the right capability, ambition and culture to help make this a reality. I believe we have created an entirely new proposition, an end-to-end partnership that can disrupt the standard agency model, challenge traditional thinking and bring something genuinely exciting to our clients.”

Synetic is a management consulting firm dedicated to the life sciences industry. Its focus is on supporting clients globally with the design and implementation of operating models including building effective strategies, processes, capabilities and organisational constructs, as well as supporting robust planning and execution across the asset life cycle. Synetic’s expertise enables bespoke solution development that supports clients in building fit for purpose operating models for commercial success.

Matthew McLoughlin, Synetic founder and CEO commented: “We are excited about our future with Lucid and our ability to achieve so much more together. This combination will enable us to support clients all the way from strategy through design of operating models to seamless implementation at the portfolio and asset level. In addition to the successful track record and growth of Lucid, what also stood out for us was that we share a very similar mission and vision for our businesses.”

Havas Health & You and Trinity Life Sciences Announce Strategic Partnership

Lucid Group acquires leading consulting firm Synetic Life Sciences